Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. - Takumida H; Horinouchi H; Masuda K; Shinno Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y (Cancer immunology, immunotherapy : CII, 2022)